FrancophonIA/ELRC3.0 huggingface dataset:
English: • to remind that patients receiving Bortezomib Hospira in combination with thalidomide should adhere to the pregnancy prevention programme of thalidomide, with reference to the SmPC of thalidomide for additional information.
Danish: • Påmindelse om, at patienter, der får Bortezomib Hospira i kombination med thalidomid, skal overholde det svangerskabsforebyggende program for thalidomid, med henvisning til produktresuméet for thalidomid for yderligere oplysninger.
English: An open label, randomised, Phase III non-inferiority study compared the efficacy and safety of the subcutaneous administration of bortezomib versus the intravenous administration.
Danish: Der er gennemført et åbent, randomiseret, fase III noninferioritetsforsøg til sammenligning af effekten og sikkerheden ved subkutan administration af bortezomib vs. intravenøs administration.
English: Therefore, this specific regimen with concomitant administration with high-dose cytarabine (2 g/m2 per day) by continuous infusion over
Danish: Derfor frarådes det at anvende dette regimen med samtidig administration af højdosis cytarabin (2 g/m dagligt) som kontinuerlig infusion over en periode på 24 timer.
English: Currently available data are described in section 5.1 but no recommendation on a posology can be made.
Danish: 5.1, men der kan ikke gives dosisanbefaling.
English: There have been fatal cases of inadvertent intrathecal administration of bortezomib.
Danish: Der er forekommet fatale tilfælde af utilsigtet intratekal administration af bortezomib.
English: 1.3 The reconstituted product is preservative free and should be used immediately after preparation.
Danish: 1.3 Det rekonstituerede produkt indeholder ingen konserveringsmidler og skal anvendes umiddelbart efter klargøring.
English: Melphalan and prednisone should both be given orally on days 1, 2, 3 and 4 of the first week of each Bortezomib Hospira treatment cycle.
Danish: Melphalan og prednison skal begge gives oralt på dag 1, 2, 3 og 4 i den første uge af hver behandlingscyklus med Bortezomib Hospira.
English: • Infections including urinary tract infections, the flu, herpes virus infections, ear infection and cellulitis
Danish: • Infektioner, herunder urinvejsinfektioner, influenza, herpes virus-infektioner, øreinfektion og cellulitis
English: Because of the potential for serious adverse reactions in breast-fed infants, breast-feeding should be discontinued during treatment with Bortezomib Hospira.
Danish: På grund af risiko for alvorlige bivirkninger hos ammede børn bør amning ophøre under behandling med Bortezomib Hospira.
English: Autologous stem cell transplants were received by 198 (82%) patients and 208 (87%) patients in the VDDx and BDx groups respectively; the majority of patients underwent one single transplant procedure.
Danish: Henholdsvis 198 (82%) og 208 (87%) patienter i VDDx og BDx-gruppen fik autolog stamcelletransplantation.
English: Other medicines and Bortezomib Hospira Please tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
Danish: Brug af anden medicin sammen med Bortezomib Hospira Fortæl altid lægen eller apotekspersonalet, hvis du bruger anden medicin eller har gjort det for nylig.
English: • Herpes virus infections
Danish: • Herpes virus-infektioner
English: Hazard ratio estimate is based on a Cox's model stratified by IPI risk and stage of disease.
Danish: Hazard ratio-estimatet er baseret på en Cox-model stratificeret efter IPI-risiko og sygdomsstadie.
English: The 1 mg, 2.5 mg, 3 mg and 3.5 mg vial can be administered subcutaneously, as described below.
Danish: Hætteglasset med 1 mg, 2,5 mg, 3 mg og 3,5 mg kan administreres subkutant som beskrevet nedenfor:
English: #, Different degrees of visual impairment (up to blindness)*
Danish: #, forskellige grader af synsnedsættelse (inkl.
English: Patients should be closely monitored when given Bortezomib Hospira in combination with potent CYP3A4-inhibitors.
Danish: Patienterne skal monitoreres nøje, når Bortezomib Hospira gives sammen med kraftige CYP3A4hæmmere.
English: Week B (1.3 mg/m
Danish: Uge B (1,3 mg/m
English: 1-year Overall Survival (%) (95% CI)
Danish: Samlet overlevelse efter 1 år (%) (95% CI)
English: • symptoms of tumor lysis syndrome such as muscle cramping, muscle weakness, confusion, visual loss or disturbances and shortness of breath
Danish: • symptomer på tumorlysesyndrom, såsom muskelkramper, muskelsvaghed, forvirring, synstab eller synsforstyrrelser og stakåndethed
English: Combination therapy with melphalan and prednisone Bortezomib Hospira is administered via intravenous or subcutaneous injection in combination with oral melphalan and oral prednisone as shown in Table 2.
Danish: Kombinationsbehandling med melphalan og prednison Bortezomib Hospira indgives som intravenøs eller subkutan injektion kombineret med oral melphalan og oral prednison som vist i tabel 2.
English: Day 8 rest period
Danish: Dag 8 Pause
English: Bortezomib Hospira therapy should be withheld when the platelet count is < 25,000/μl or, in the case of combination with melphalan and prednisone, when the platelet count is ≤ 30,000/μl (see section 4.2).
Danish: Behandlingen med Bortezomib Hospira skal afbrydes, når thrombocyttallet er < 25.000/μl eller, ved kombinationsbehandling med melphalan og prednison, når thrombocyttallet er ≤ 30.000/μl (se pkt.4.2).
English: The following medicinal products are administered on day 1 of each Bortezomib Hospira 3 week treatment cycle as intravenous infusions: rituximab at 375 mg/m 2, cyclophosphamide at 750 mg/m 2 and doxorubicin at 50 mg/m
Danish: Følgende lægemidler administreres som intravenøse infusioner på dag 1 i hver 3-ugers behandlingscyklus med Bortezomib Hospira: rituximab 375 mg/m 2, cyclophosphamid 750 mg/m 2 og doxorubicin 50 mg/m
English: ≥ 1,500 cells/μL
Danish: celler/μl
English: When compared to patients with normal hepatic function, mild hepatic impairment did not alter dose-normalised bortezomib AUC.
Danish: Sammenlignet med patienter med normal leverfunktion ændrede en let nedsættelse af leverfunktionen ikke dosis-normaliseret AUC for bortezomib.
English: Patients in the BTDx and TDx groups respectively had a median age of 57 versus 56 years, 99% versus 98% patients were Caucasians, and 58% versus 54% were males.
Danish: Patienterne i henholdsvis BTDx- og TDx-gruppen havde en medianalder på 57 vs. 56 år, 99% vs. 98 af patienterne var af kaukasisk oprindelse, og 58% vs. 54% var mænd.
English: The benefit/risk ratio should be considered prior to continuing Bortezomib Hospira therapy.
Danish: Forholdet mellem fordele og risici skal overvejes, før behandlingen med Bortezomib Hospira fortsætter.
English: • Increased heartbeat, high blood pressure, sweating,
Danish: • Hurtigere hjerteslag, højt blodtryk, svedeture
English: Mantel-Haenszel estimate of the common odds ratio for stratified tables is used, with IPI risk and stage of disease as stratification factors.
Danish: Mantel-Haenszel-estimat af den fælles odds ratio for stratificerede tabeller er benyttet med IPI-risiko og sygdomsstadie som stratifikationsfaktorer.
English: Bortezomib Hospira must be reconstituted by a healthcare professional (see section 6.6).
Danish: Bortezomib Hospira skal rekonstitueres af sundhedspersonale (se pkt.
English: Anaphylactic shock, Amyloidosis, Type III immune complex mediated reaction
Danish: Sjælden Anafylaktisk shock, amyloidose, immunkompleks-medieret (type III) reaktion
English: OR e (95% CI)=1.688
Danish: (95% CI)=1,688
English: • in combination with the medicines dexamethasone or dexamethasone together with thalidomide, for patients whose disease has not been previously treated and before receiving high-dose chemotherapy with blood stem cell transplantation (induction treatment).
Danish: • sammen med lægemidlerne dexamethason eller dexamethason sammen med thalidomid til patienter, hvis sygdom ikke tidligere er blevet behandlet, og før de får højdosis-kemoterapi med transplantation af blodstamceller (induktionsbehandling)
English: Table 2: Recommended posology for Bortezomib Hospira in combination with melphalan and prednisone Twice weekly Bortezomib Hospira (cycles 1-4)
Danish: Tabel 2: Anbefalet dosering af Bortezomib Hospira i kombination med melphalan og prednison Bortezomib Hospira 2 gange om ugen (cyklus 1-4)
English: Rituximab at 375 mg/m2 , cyclophosphamide at 750 mg/m2 and doxorubicin at 50 mg/m2.
Danish: Rituximab 375 mg/m2, cyclophosphamid 750 mg/m2 og doxorubicin 50 mg/m2.
English: • Swelling of body, to include around eyes and other parts of the body
Danish: • Hævelser på kroppen, blandt andet omkring øjnene og andre steder på kroppen
English: * Primary endpoint
Danish: * Primært endepunkt
English: The incidence of herpes zoster among patients in the BR-CAP arm was 10.7% for patients not administered antiviral prophylaxis compared to 3.6% for patients administered antiviral prophylaxis (see section 4.4).
Danish: Forekomsten af herpes zoster blandt patienter i BR-CAP-gruppen var 10,7% hos patienter, der ikke havde fået antiviral profylakse, sammenlignet med 3,6% hos patienter, der havde fået antiviral profylakse (se pkt.
English: Discontinue Bortezomib Hospira if PML is diagnosed.
Danish: Bortezomib Hospira skal seponeres, hvis PML diagnosticeres.
English: Urinary tract infection*
Danish: Urinvejsinfektion*
English: A median of 6 cycles was received by patients in both treatment arms with 14% of subjects in the BR-CAP group and 17% of patients in the R-CHOP group receiving 2 additional cycles.
Danish: Patienterne i begge behandlingsgrupper fik et medianantal cyklusser på 6, hvor 14% af patienterne i BR-CAP-gruppen og 17% af patienterne i R-CHOP-gruppen fik 2 supplerende cyklusser.
English: The usual starting dose of bortezomib is 1.3 mg/m2 body surface area twice a week.
Danish: Den sædvanlige startdosis af bortezomib er 1,3 mg/m2 legemsoverfladeareal to gange om ugen.
English: Hypersensitivity* Uncommon Anaphylactic reaction
Danish: Overfølsomhed* Ikke almindelig Anafylaktisk reaktion
English: Bortezomib Hospira treatment must be withheld at the onset of any ≥ Grade 3 bortezomib-related non-haematological toxicities (excluding neuropathy) or ≥ Grade 3 haematological toxicities (see also section 4.4).
Danish: Behandling med Bortezomib Hospira skal afbrydes ved forekomst af ≥ grad 3 bortezomib-relaterede ikke-hæmatologiske toksiciteter (undtagen neuropati) eller ≥ grad 3 hæmatologiske toksiciteter (se også pkt.
English: The median TTP was 6.5 months for the bortezomib monotherapy patients compared with 9.3 months for the bortezomib plus pegylated liposomal doxorubicin combination therapy patients.
Danish: Median-TTP var 6,5 måneder for patienter i monoterapi med bortezomib sammenlignet med 9,3 måneder for patienter i kombinationsbehandling med bortezomib plus pegyleret liposomal doxorubicin.
English: BR-CAP= bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone; R-CHOP= rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; PN=peripheral neuropathy
Danish: BR-CAP= bortezomib, rituximab, cyclophosphamid, doxorubicin og prednison; R-CHOP= rituximab, cyclophosphamid, doxorubicin, vincristin og prednison; PN=perifer neuropati
English: Therefore, patients should be closely monitored when given bortezomib in combination with potent CYP3A4 inhibitors (e.g. ketoconazole, ritonavir).
Danish: Patienterne skal derfor monitoreres omhyggeligt, når bortezomib gives sammen med kraftige CYP3A4-hæmmere (f.eks. ketoconazol, ritonavir).
English: The pharmacokinetics of bortezomib were characterized following twice weekly intravenous bolus administration of 1.3 mg/m2 doses to 104 paediatric patients (2-16 years old) with acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML).
Danish: Alder Bortezomibs farmakokinetik er beskrevet efter intravenøs bolus-administration af 1,3 mg/m2 2 gange om ugen til 104 pædiatriske patienter (2-16 år) med akut lymfoblast leukæmi (ALL) eller akut myeloid leukæmi (AML).
English: Therefore, you will have to take regular blood tests before and during your treatment with bortezomib, to check your blood cell counts regularly.
Danish: Du vil derfor regelmæssigt få taget blodprøver før og under din behandling med bortezomib for at kontrollere dine blodtal.
English: Gastrointestinal and intracerebral haemorrhage, have been reported in association with bortezomib treatment.
Danish: Gastrointestinal og intracerebral blødning er blevet indberettet i forbindelse med behandling med bortezomib.
English: Change Bortezomib Hospira treatment schedule to 1.3 mg/m2 once per week
Danish: Skift behandlingsplan for Bortezomib Hospira til 1,3 mg/m én gang om ugen
English: Bortezomib Hospira may be associated with fatigue very commonly, dizziness commonly, syncope uncommonly and orthostatic/postural hypotension or blurred vision commonly.
Danish: Bortezomib Hospira kan være forbundet med træthed (meget almindeligt), svimmelhed (almindeligt), synkope (ikke almindeligt) og ortostatisk/postural hypotension eller sløret syn (almindeligt).
English: Bortezomib Hospira should not be given by other routes.
Danish: Bortezomib Hospira må ikke indgives via andre administrationsveje.
English: Normal liver function should be confirmed and caution should be exercised in patients receiving oral hypoglycaemics (see section 4.5).
Danish: En normal leverfunktion skal bekræftes, og der skal udvises forsigtighed hos patienter, der behandles med orale antidiabetika (se pkt.
English: Potentially immunocomplex-mediated reactions, such as serum-sickness-type reaction, polyarthritis with rash and proliferative glomerulonephritis have been reported uncommonly.
Danish: Der er i sjældne tilfælde indberettet potentielt immunkompleksmedierede reaktioner, for eksempel serumsyge, polyarthritis med udslæt og proliferativ glomerulonefritis.
English: Posology modification
Danish: Doseringsændring
English: • Loss of consciousness
Danish: • Bevidsthedstab
English: Table 16: Efficacy results from study LYM-3002 Efficacy endpoint
Danish: Tabel 16: Effektresultater fra forsøg LYM-3002 Effektendepunkt
English: Seizures have been uncommonly reported in patients without previous history of seizures or epilepsy.
Danish: Der er indberettet enkelte tilfælde af krampeanfald hos patienter, som ikke tidligere har haft sådanne anfald eller epilepsi.
English: • Bortezomib Hospira 1 mg, 2.5 mg, 3 mg and 3.5 mg can be administered both intravenously and subcutaneously
Danish: • Information om, at Bortezomib Hospira 1 mg, 2,5 mg, 3 mg og 3,5 mg kan administreres både intravenøst og subkutant
English: • Altered levels of consciousness, confusion, memory impairment or loss
Danish: • Forandringer i bevidsthedsniveau, forvirring, nedsat hukommelse eller hukommelsestab
English: Induction Transplant Regimens Graph shall contain the following key elements:
Danish: Diagrammet over regimer med induktionstransplantation skal indeholde følgende nøgleelementer:
English: Reduce Bortezomib Hospira to 1.0 mg/m or
Danish: Nedsæt Bortezomib Hospira til 1,0 mg/m eller
English: • Problems with your ear, bleeding from your ear
Danish: • Øreproblemer, blødning fra ørerne
English: A total of 74 evaluable patients were administered dexamethasone in combination with bortezomib.
Danish: I alt har 74 evaluerbare patienter fået dexamethason sammen med bortezomib.
English: Table 3: Posology modifications during subsequent cycles of Bortezomib Hospira therapy in combination with melphalan and prednisone
Danish: Tabel 3: Dosisjusteringer under efterfølgende cyklusser med Bortezomib Hospira i kombination med melphalan og prednison
English: A Phase II, single-arm activity, safety, and pharmacokinetic trial conducted by the Children's Oncology Group assessed the activity of the addition of bortezomib to multi agent re induction chemotherapy in paediatric and young adult patients with lymphoid malignancies (pre-B cell acute lymphoblastic leukemia [ALL], T-cell ALL, and T-cell lymphoblastic lymphoma [LL]).
Danish: Et fase II-forsøg med en enkelt behandlingsgruppe og undersøgelse af aktivitet, sikkerhed og farmakokinetik, udført af Children's Oncology Group, vurderede man virkningen af at tilføje bortezomib til reinduktionskemoterapi med flere stoffer hos pædiatriske og unge voksne patienter med lymfoide maligniteter (akut præ-B-celle lymfoblast leukæmi [ALL], T-celle-ALL og T-celle lymfoblast lymfom [LL]).
English: When bortezomib is given in combination with thalidomide you must follow the pregnancy prevention programme for thalidomide (see package leaflet for thalidomide).
Danish: Hvis du får Bortezomib Hospira sammen med thalidomid, skal du følge det svangerskabsforebyggende program for thalidomid (se indlægssedlen for thalidomid).
English: Table 10: Incidence of peripheral neuropathy in study LYM-3002 by toxicity and treatment discontinuation due to peripheral neuropathy
Danish: Tabel 10: Forekomsten af perifer neuropati i forsøg LYM-3002, inddelt efter toksicitet og behandlingsseponering på grund af perifer neuropati
English: Antiviral prophylaxis is recommended in patients being treated with Bortezomib Hospira.
Danish: Antiviral profylakse bør overvejes til patienter, der behandles med Bortezomib Hospira.
English: In the Phase III study comparing bortezomib administered intravenously versus subcutaneously, the incidence of Grade ≥ 2 peripheral neuropathy events was 24% for the subcutaneous injection group and 41% for the intravenous injection group (p=0.0124).
Danish: I fase III-forsøget til sammenligning af bortezomib administreret intravenøst vs. subkutant var forekomsten af bivirkninger med perifer neuropati ≥ grad 2 24% i gruppen, der fik subkutane injektioner, og 41% i gruppen, der fik intravenøse injektioner (p=0,0124).
English: As this medicine is being given by your doctor or nurse, it is unlikely that you will be given too much.
Danish: Hvis du har fået for meget Bortezomib Hospira Da dette lægemiddel gives af en læge eller sygeplejerske, er det usandsynligt, at du vil få for meget.
English: Day rest period
Danish: Pause Dag
English: There have been fatal cases of inadvertent intrathecal administration of Bortezomib Hospira.
Danish: Der har været fatale tilfælde af utilsigtet intratekal administration af Bortezomib Hospira.
English: Platelet transfusion should be considered when clinically appropriate (see section 4.2).
Danish: Thrombocyttransfusion skal overvejes, når det er klinisk relevant (se pkt.
English: The Reconstitution poster shall contain the following key elements:
Danish: Plakaten om rekonstitution skal indeholde følgende hovedpunkter:
English: Although in patients aged ≥ 75 years, both BR-CAP and R-CHOP were less tolerated, the serious adverse event rate in the BR-CAP groups was 68%, compared to 42% in the R-CHOP group.
Danish: Både BR-CAP og R-CHOP er mindre veltolereret hos patienter ≥ 75 år, og hyppigheden af alvorlige bivirkninger er i BR-CAP-gruppen 68% sammenlignet med 42% i R-CHOP-gruppen.
English: • Induction Transplant Regimens Graph.
Danish: • Diagram over regimer med induktionstransplantation.
English: Patients receiving Bortezomib Hospira in combination with thalidomide should adhere to the pregnancy prevention programme of thalidomide.
Danish: Patienter, der får Bortezomib Hospira i kombination med thalidomid, skal overholde det særlige svangerskabsforebyggende program for thalidomid.
English: Grade ≥ 3 non-haematological toxicities
Danish: Ikke-hæmatologiske toksiciteter grad ≥ 3
English: The AUClast- geometric mean ratio was 0.99 and 90% confidence intervals were
Danish: Den geometriske gennemsnitsratio AUClast var 0,99, og 90% konfidensintervaller var 80,18%-122,80%.
English: In patients with advanced myeloma the severity of thrombocytopenia was related to pre-treatment platelet count: for baseline platelet counts < 75,000/μl, 90% of 21 patients had a count ≤ 25,000/μl during the study, including 14% < 10,000/μl; in contrast, with a baseline platelet count > 75,000/μl, only 14% of 309 patients had a count ≤ 25,000/μl during the study.
Danish: Hos patienter med fremskredent myelom var sværhedsgraden af thrombocytopeni forbundet med thrombocyttallet inden behandlingen: Med et thrombocyttal ved baseline på < 75.000/μl havde 90% af 21 patienter et tal på ≤ 25.000/μl under forsøget, herunder 14% på < 10.000/μl.
English: Patients who experience bortezomib-related neuropathic pain and/or peripheral neuropathy are to be managed as presented in Table 1 (see section 4.4).
Danish: Patienter, som har bortezomib-relaterede neuropatiske smerter og/eller perifer neuropati, skal behandles som vist i tabel 1 (se pkt.
English: The mean distribution volume (Vd) of bortezomib ranged from 1,659 l to 3,294 l following single- or repeated-dose intravenous administration of 1.0 mg/m2 or 1.3 mg/m2 to patients with multiple myeloma.
Danish: Det gennemsnitlige distributionsvolumen (Vd) for bortezomib er 1.659-3.294 l efter administration af intravenøse enkeltdoser eller gentagne doser på 1,0 mg/m2 eller 1,3 mg/m2 til patienter med myelomatose.
English: Table 6: Recommended starting dose modification for Bortezomib Hospira in patients with hepatic impairment Grade of hepatic impairment*
Danish: Tabel 6: Anbefalet justering af initialdosis af Bortezomib Hospira hos patienter med nedsat leverfunktion Grad af leversvækkelse*
English: A 6-week period is considered a treatment cycle.
Danish: En periode på 6 uger anses for at være en behandlingscyklus.
English: You must read the package leaflets of all medicinal products to be taken in combination with Bortezomib Hospira for information related to these medicines before starting treatment with Bortezomib Hospira.
Danish: Læs indlægssedlerne for alle de lægemidler, du skal tage sammen med Bortezomib Hospira, for at få oplysninger om disse lægemidler, før du begynder på behandlingen med Bortezomib Hospira.
English: Bortezomib combination treatment with dexamethasone In the absence of any direct comparison between bortezomib and bortezomib in combination with dexamethasone in patients with progressive multiple myeloma, a statistical matched-pair analysis was conducted to compare results from the non randomised arm of bortezomib in combination with dexamethasone (Phase II open-label study MMY-2045), with results obtained in the bortezomib monotherapy arms from different Phase III randomised studies (M34101-039 [APEX] and DOXIL MMY-3001) in the same indication.
Danish: Bortezomib-kombinationsbehandling med dexamethason I mangel af en direkte sammenligning af bortezomib og bortezomib i kombination med dexamethason hos patienter med progressiv myelomatose blev der gennemført en statistisk "matchede par"-analyse for at sammenligne resultaterne fra den ikke-randomiserede gruppe med bortezomib i kombination med dexamethason (åbent fase II-forsøg, MMY-2045) med resultaterne fra grupperne i monoterapi med bortezomib fra forskellige randomiserede fase III-forsøg (M34101-039 [APEX] og DOXIL MMY-3001) med samme indikation.
English: • Ringing in the ears, ear discomfort
Danish: • Ringen for ørerne, ubehag i ørerne
English: BTDx=bortezomib, thalidomide, dexamethasone; PN=peripheral neuropathy Note: Peripheral neuropathy included the preferred terms: neuropathy peripheral, peripheral motor neuropathy, peripheral sensory neuropathy, and polyneuropathy.
Danish: BTDx=bortezomib, thalidomid, dexamethason; PN=perifer neuropati Bemærk: Perifer neuropati omfatter de foretrukne termer: perifer neuropati, perifer motorisk neuropati, perifer sensorisk neuropati og polyneuropati.
English: • ketoconazole, used to treat fungal infections
Danish: • ketoconazol, der bruges til behandling af svampeinfektioner
English: SGOT (AST) levels
Danish: SGOTniveau (ASAT)
English: Bortezomib might cause tiredness, dizziness, fainting, or blurred vision.
Danish: Bortezomib Hospira kan forårsage træthed, svimmelhed, besvimelse eller sløret syn.
English: The median OS was 30.8 months (95% CI; 25.2-36.5 months) for the bortezomib monotherapy patients and 33.0 months (95% CI; 28.9-37.1 months) for the bortezomib plus pegylated liposomal doxorubicin combination therapy patients.
Danish: Median-OS var 30,8 måneder (95% CI; 25,2-36,5 måneder) patienter i monoterapi med bortezomib og 33,0 måneder (95% CI; 28,937,1 måneder) for patienter i kombinationsbehandling med bortezomib plus pegyleret liposomal doxorubicin.